Stephan Rogalla

Appearances

BIOLOGIC USE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND RISK OF GASTROINTESTINAL INFECTIONS: A PROPENSITY-MATCHED NATIONAL DATABASE COHORT ANALYSIS
Date
May 9, 2023
BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
Presenter
John Mark Gubatan
Speakers
Saurabh Gombar
Kian Keyashian
Stephan Rogalla
Sidhartha Sinha
ELEVATED OSM/OSMR EXPRESSION IN INFLAMED MUCOSAL TISSUE REFLECTS AN INFLAMMATORY CASCADE MEDIATED BY NEUTROPHIL:STROMAL INTERACTIONS ASSOCIATED WITH RESIDUAL DISEASE IN TREATMENT-REFRACTORY UC PATIENTS
Date
May 21, 2024
OSM-OSMR signaling is associated with IBD disease severity and non-response to anti-TNFs, and OSMR expression is associated with inflammatory fibroblasts…
Presenter
Shadi Eshghi
Speakers
Jason Hackney
Olusegun Onabajo
Rojo Ratsimandresy
Mary Keir
Luis Quintanilla
Parisa Mazrooei
Yongchang Shi
Jerry Wang
Ephraim Kenigsberg
Allen Nguyen
John Mark Gubatan
Stephan Rogalla
Derek Holman
Amelia Au-Yeung
Chikara Takahashi
William O’Gorman
Horace Rhee
Jacqueline McBride
MOLECULAR CHARACTERIZATION OF RESPONSE TO ETROLIZUMAB AND ANTI-TNF REVEALS TREATMENT REFRACTORY ULCERATIVE COLITIS IS ASSOCIATED WITH ABUNDANCE OF RESIDUAL NEUTROPHIL SUBSETS AND ACTIVE FIBROBLAST POPULATIONS
Date
May 19, 2024
BACKGROUND: HIBISCUS I/II assessed the efficacy of etrolizumab versus adalimumab with a 10-week induction regimen in patients with ulcerative colitis (UC)…
Speakers
Shadi Eshghi
John Mark Gubatan
Parisa Mazrooei
Luis Quintanilla
Allen Nguyen
Amelia Au-Yeung
Derek Holman
Courtney Schiffman
William O'Gorman
Chikara Takahashi
Mary Keir
Stephan Rogalla
Jason Hackney
Presenter
Jacqueline McBride